

Title: Utility of IL-6 in the diagnosis, treatment and prognosis of COVID-19 patients: A longitudinal study

Authors: Vikram Jain¹, Pratap Kumar¹, Prasan Kumar Panda¹, Karan Kaushal², Anissa A Mirza², Vivekandan S²

Affiliations: ¹*Department of Internal Medicine (ID Division)*, ²*Department of Biochemistry, AIIMS Rishikesh*

Emails: vikramjetawat99@gmail.com, pkmaharaj15@gmail.com,
motherprasanna@rediffmail.com,
karanvirkaushal@gmail.com, anissa.bchem@aiimsrishikesh.edu.in, svivek_aiims@yahoo.com

Corresponding author

Prasan Kumar Panda
Asso. Professor, Dept. of Medicine,
Sixth Floor, College Block,
All India Institute of Medical Sciences (AIIMS),
Rishikesh, India, 249203
Mob: +91-9868999488
motherprasanna@rediffmail.com

Abstract

Introduction: Covid-19 has caused devastating effects worldwide ever since its origin in December, 2019. Till date, there is no definitive treatment for it. Deaths due to Covid-19 has largely been attributed to cytokine storm and organ dysfunctions, mainly ARDS. Therefore, the focus has been on using inflammatory markers as a marker of severity of the disease. IL-6 is one such marker which has been increasingly used in the management of Covid-19. We conducted a longitudinal study to investigate the role of IL-6 in diagnosis, treatment and prognosis of Covid-19 related cytokine storm.

Methodology: Patients with Covid-19, who were admitted at AIIMS Rishikesh from March to December, 2020 were included in the study. Patients with no baseline IL-6 value at admission and for whom clinical data was not available were excluded. Clinical and laboratory data of these patients were collected from the e-hospital portal and entered in excel sheet. Correlation was seen with other inflammatory markers and outcomes were assessed using MS Excel 2010 and SPSS software.

Results: At total of 131 patients were included in the study. Majority were males (74.8%), mean age of the subjects being 55.03 ± 13.57 years, with a mean duration from symptom onset being 6.69 ± 6.3 days. Most of them belonged to the WHO severe category (82.4%), with 46.56% having severe hypoxia at presentation and 61.8% of them having some comorbidity- diabetes mellitus being the commonest. Spearman Rank Correlation coefficient of IL-6 with D-dimer was 0.203, with LDH was -0.005, with Ferritin was 0.3, and with Uric acid was 0.123. 11 patients received Tocilizumab at a mean duration from symptom onset of 18.09 days, and 100% mortality was observed. Deaths were reported more in the group with IL-6 more than 40pg/ml (57.1% vs 40.2%, $p=0.06$). Similarly, ICU admissions and ventilator requirement were reported more in the IL-6 more than 40pg/ml group (95.9% vs 91.4%, $p=0.32$ and 55.1% vs 37.8%, $p=0.05$).

Conclusion: The study showed that IL-6 can be used as a possible thrombotic cytokine marker. Higher values of IL-6 (≥ 40 pg/ml) are associated with more deaths, ICU admissions and ventilator requirement.

Key Words: Cytokine storm, Ferritin, LDH, D-dimer, SARS-Cov2, Coronavirus

Introduction

Covid-19 is a viral illness caused by SARS-CoV-2 infection in humans. It is a respiratory pathogen, transmitted by close contact and droplets. The viral infection may be asymptomatic in up to 15.6 % of individuals(1) and may cause symptoms in others. The main symptoms of the illness include fever, dry cough and fatigue. Other symptoms include loss of taste, nasal congestion, sore throat, conjunctivitis, headache, myalgia, nausea, vomiting , diarrhoea etc.(2) The disease has drawn worldwide attention ever since its first detection in December, 2019 and despite several efforts globally, it has spread across the world and has caused a health disaster. According to WHO, as of 8th July 2022, 5:33pm -551,226,298 confirmed cases and 6,345,595 deaths have been reported worldwide due to Covid-19.(3) In India, there the toll of confirmed Covid-19 cases has reached 43,585,554 with 525,343 deaths related to Covid-19.(3) The disease has caused long lasting effects in many patients- dyspnoea, psychiatric issues (anxiety, panic disorder, etc.).

Certain viruses such as highly pathogenic SARS-CoV-2, IAV, and Ebola viruses induce excessive and prolonged cytokine/chemokine response known as “cytokine storms,” which results in high morbidity and mortality due to immunopathology (10). Inflammatory markers, especially IL-6, CRP, PCT, and ESR, have been positively correlated with the severity of COVID-19 (11). As of now due to lack of definitive antiviral therapy against Covid-19, targeted immunotherapy has become treatment of choice in this massacre (12). Out of all inflammatory markers, therapy against IL-6, Tocilizumab reduces 28-30□ days all-cause mortality, ICU admission, super infections, mechanical ventilation and the combined endpoint of death or mechanical ventilation (13).

Due to lack of studies showing integration of all the major role of IL-6 in Covid-19 illness, here we performed a longitudinal study showing role of IL-6 in diagnosis, treatment and prognosis of Covid-19 related disease. This study will further strengthen our knowledge regarding IL-6 and covid-19 disease.

Methodology

The Approval for this study was obtained from institute ethics committee of AIIMS Rishikesh with approval no CTRI/2020/08/027169.

The study population comprises of patients of age 18 years and above with diagnosis of Covid-19 (clinicoradiologically or positive covid RTPCR testing of oropharyngeal and

nasopharyngeal swabs) who were admitted at AIIMS Rishikesh during the 1st Covid-19 wave (from March, 2020 to December, 2020). The patients who were not having baseline IL-6 at admission and incomplete data in online e-hospital portal entry were excluded from the study.

All the demographic details which included age, gender and clinical details like chief complaints, comorbidities, various investigations- routine blood investigations, inflammatory markers, radiological investigations, treatment given, outcome (death or discharge), ICU stay, mechanical ventilation were obtained from the e-hospital portal of the institute and entered into an excel sheet at the timeline of 0, 2, 7,14,21,28 days from the duration of symptom onset. It was mandatory for all the patients to have a baseline IL-6 at the time of admission. The patients who were having raised IL-6 received Tocilizumab based upon the clinician's decision and availability.

The primary outcome was to assess the correlation of IL-6 with other inflammatory markers, to see the proportion of patients with raised IL-6 requiring ICU admission and mechanical ventilation, to look for death in the patients with raised IL-6 and to see effect of IL-6 antagonist, Tocilizumab in the outcome.

The data was entered in Microsoft excel 2010 and analysed using excel, and SPSS software. For outcome analysis, patients were divided into two groups- high IL-6 (IL-6 \geq 40pg/ml) and low IL-6 (IL-6 <40pg/ml). Spearman rank correlation coefficient was calculated to see how IL6 values correlated with the other inflammatory markers. Chi-square test was used to see the statistical significance of outcome prediction with IL6.

Results

We identified 213 patients out of which 73 were excluded as baseline IL-6 data was not available and later on 9 were excluded because of incomplete data in e-hospital portal. Remaining 131 patients were included in the study (Fig. 1).

Baseline characteristics of all the patients are shown in Table 1. Mean duration from symptom onset at presentation was 6.69 ± 6.3 days and out of 131 patients, 82.4% patients had severe Covid according to WHO and 46.5% of patients had severe hypoxia.




Fig1: Flow of study

Parameter	
Total subjects	131
Gender	
Male	98
Female	33
Mean age	55.03±13.57 years
Mean duration from symptom onset at presentation	6.69±6.3 days
Comorbidities	
None	50
T2DM	56
HTN	46
CAD	11

COPD	12
CVA	2
CKD	3
CLD	2
Autoimmune disease	5
Malignancy	3
Mean Charlson comorbidity index	2
Severity of Covid-19 at presentation (WHO)	
Mild	2
Moderate	21
Severe	108
Severity of Covid-19 at presentation(qCSI score)	
Low risk (0-3)	32
Low intermediate risk (4-6)	34
High intermediate risk (7-9)	1
High risk (10-12)	0
Respiratory failure at presentation	
No hypoxia	11
Mild hypoxia (P/F: 201-300)	13
Moderate hypoxia (P/F= 101-200)	41
Severe hypoxia(P/F= <100)	61

Table1: General characteristics of the patients at admission

Largely four inflammatory biomarkers Ferritin, D-dimer, LDH, uric acid were measured and correlation was shown with IL-6 in the form of Spearman rank correlation coefficient. The spearman rank correlation coefficient of IL-6 with D-dimer was 0.203(n=43), with ferritin was 0.3(n=15), with LDH was -0.005(n=20), with Uric acid was 0.123(n=77). Fig2 shows the scatterplot of IL-6 with inflammatory markers.




Fig2: Correlation of IL-6 with various inflammatory markers

In hospital death was considered as important outcome assessor and compared in both the groups. Death was reported more in patients with raised IL-6 compared with lower IL-6 value (57.1% vs 40.2%, n=131, p=0.06) (Fig. 3). The need of ICU admission and mechanical ventilation was also more in patients with raised IL-6, 95.9% vs 91.2% (n=131, p=0.32) and 55.1% vs 37.8% (n=131, p=0.054) respectively (Fig. 4&5). The duration of hospital and ICU stay was higher in group of raised IL-6 (22.4 vs 18.6 days=0.12 and 17.58 vs 14.44 days=0.16). IL-6 antagonist, Tocilizumab was administered in 11 patients with raised IL-6 value after a mean duration from symptom onset of 18.09 days and death was reported in 100% of patient.




Fig. 3: Comparison of deaths between the groups




Fig. 4: Comparison of need for ICU stay between the groups




Fig. 5: Comparison of IMV requirement between the groups

Discussion

Despite introduction of vaccines, Covid-19 related breakthrough infections are still high in various part of the world (14). It has become essential to find out markers of severe disease and treat them on early basis to stop the incoming of new covid related massacre as we have experienced early (15). IL-6 is among the few potential biomarkers whose level can predict the development of severe covid pneumonia (16) and its antagonist could help us preventing this if used within a given period of time(17)(18).

In our knowledge, our study is first among all to correlate IL-6 with other inflammatory markers in covid and show its role in treatment and prognosis of the disease. Increase in inflammatory markers in viral infection is part of cytokine storm which is characterised by hyper production of pro inflammatory cytokines causing initiation of different signalling pathways and resulting into complicated medical symptoms including fever, capillary leak syndrome, acute respiratory distress syndrome, and multiorgan failure, ultimately leading to death in the most severe cases (19). Rise in levels of D-dimer is due to activation of inflammatory pathways secondary to imbalance between coagulation and fibrinolysis primarily in alveolus (20) (21). Our study showed mild positive correlation of IL-6 with D-dimer ($R= 0.203$). Level of LDH rises non-specifically in the pathological condition of lungs like inflammation and cell damage (22). Serum LDH levels have been used as an independent marker of covid severity and predictor of mortality in covid (23) (24). Our study showed a weak correlation of IL-6 with LDH ($R= -0.005$). Uric acid acts as an antioxidant scavenging

oxygen free radicals and protect cells from oxidative damages (25) (26) (27). Levels of uric acid can be used as prognostic marker in severe covid infection (28). Our study showed weak positive correlation of IL-6 with serum uric acid levels ($R=0.123$). Serum ferritin being an acute phase reactant mirrors the degree of acute inflammation inside the body. Higher ferritin levels indicates activation of monocyte-macrophage system in body and it is responsive to alteration of cytokines levels in blood (29). Higher ferritin levels are associated with more severe disease and negative or poor outcome in covid disease (30). Our study has shown weak correlation of IL-6 with ferritin ($R=0.3$).

A raised level of serum IL-6 (cut off - 35pg/ml) is associated with increased mortality and can be useful prognostic marker in determining severity of covid (31). IL-6 value of >37.5 pg/ml is associated with higher in hospital mortality (sensitivity=91.7% and specificity=95.7%) (32). Our study used a cut-off of 40pg/ml for raised serum IL-6 levels and showed higher mortality in raised IL-6 group (57.2% vs 40.2%). Higher levels of IL-6 also correlate with more requirement of mechanical ventilation and ICU admission (33) (34). In our study, compared to the group of low IL-6, higher ICU admission (95.9% vs 91.2%) and higher incidence of mechanical ventilation (55.1% vs 37.8) along with prolonged ICU and hospital stay (17.58 vs 14.44 days and 22.4 vs 18.6 days; respectively) was found in patient with raised IL-6 group.

Addition of IL-6 antagonist is associated with absolute reduction in mortality of 4% (35). When given within 24 hours of ICU admission, treatment with IL-6 antagonists had resulted in higher incidence of hospital survival with both Tocilizumab and Sarilumab (36) (37). In 11 patients with raised IL-6 in our study, Tocilizumab was given based upon clinician's decision at a mean duration from symptom onset of 18.09 days and 100% mortality was observed.

Our study however suffers from some definite limitations. Lesser amount of data of inflammatory markers turns out to be major limitation. In our study, the administration of IL-6 antagonist, Tocilizumab was delayed because of unclassified reasons which reflect its negative impact on outcome. The sample size of this study further affects the outcome of the study to a certain extent.

Conclusion

IL-6 is an important inflammatory marker predicting severity of covid-19. The finding of our study strengthens the positive correlation of IL-6 with D-dimer. Hence IL-6 would be

considered as ‘Thrombotic cytokine storm marker’. Negligible correlation with LDH and uric acid strengthens its importance in covid illness. Findings of our study reinforces role of IL-6 as an important prognostic marker in severe covid. Also negative results after giving Tocilizumab in later during course of illness may encourage its use during initial stages of disease. Our study provides evidence that raised value of baseline IL-6 correlates with mortality.

Contributors

All authors contributed to the data collection, data analysis, and manuscript writing, critically reviewed the draft, and approved it for publication.

Data sharing

It will be made available to others as required upon requesting the corresponding author.

Acknowledgment

COVID care team was collecting data, special thanks to all of them.

Conflicts of interest

We declare that we have no conflicts of interest.

Funding source

None

References

1. He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. *J Med Virol* [Internet]. 2021 [cited 2022 Jul 30];93(2):820–30. Available from: <http://dx.doi.org/10.1002/jmv.26326>
2. Coronavirus disease (COVID-19) – World Health Organization [Internet]. Who.int. [cited 2022 Jul 30]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
3. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2020 Nov 3]. Available from: <https://covid19.who.int/>
4. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. *J Med Virol* [Internet]. 2020 [cited 2022 Jul 30];92(11):2283–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/32343429/>

5. Zeng H-L, Lu Q-B, Yang Q, Wang X, Yue D-Y, Zhang L-K, et al. Longitudinal profile of laboratory parameters and their application in the prediction for fatal outcome among patients infected with SARS-CoV-2: A retrospective cohort study. *Clin Infect Dis* [Internet]. 2021 [cited 2022 Jul 30];72(4):626–33. Available from: <https://pubmed.ncbi.nlm.nih.gov/33048116/>
6. El Aidaoui K, Haouadar A, Khalis M, Kantri A, Ziati J, El Ghanmi A, et al. Predictors of severity in covid-19 patients in Casablanca, Morocco. *Cureus* [Internet]. 2020 [cited 2022 Jul 30];12(9):e10716. Available from: <https://pubmed.ncbi.nlm.nih.gov/33033687/>
7. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. *J Med Virol* [Internet]. 2021;93(1):250–6. Available from: <http://dx.doi.org/10.1002/jmv.26232>
8. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J* [Internet]. 2003 [cited 2022 Jul 30];374(Pt 1):1–20. Available from: <https://pubmed.ncbi.nlm.nih.gov/12773095/>
9. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. *Clin Sci (Lond)* [Internet]. 2012 [cited 2022 Jul 30];122(4):143–59. Available from: <https://pubmed.ncbi.nlm.nih.gov/22029668/>
10. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* [Internet]. 2017 [cited 2022 Jul 30];39(5):529–39. Available from: <https://pubmed.ncbi.nlm.nih.gov/28466096/>
11. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. *Int J Infect Dis* [Internet]. 2020 [cited 2022 Jul 30];96:467–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/32425643/>
12. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol* [Internet]. 2020 [cited 2022 Jul 30];92(4):424–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/31981224/>
13. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. *Biomed Pharmacother* [Internet]. 2020 [cited 2022 Jul 30];131(110698):110698. Available from: <http://dx.doi.org/10.1016/j.biopha.2020.110698>
14. CDC. COVID-19 after vaccination: Possible breakthrough infection [Internet]. Centers for Disease Control and Prevention. 2022 [cited 2022 Jul 30]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html>
15. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. *Int J Infect Dis* [Internet]. 2020 [cited 2022 Jul 30];95:304–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/32344011/>
16. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19

- progression. *Med Mal Infect* [Internet]. 2020 [cited 2022 Jul 30];50(4):382–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/32259560/>
17. Gordon AC, Angus DC, Derde LPG. Interleukin-6 receptor antagonists in critically ill patients with covid-19. Reply. *N Engl J Med* [Internet]. 2021;385(12):1147–9. Available from: <http://dx.doi.org/10.1056/NEJMc2108482>
 18. Hermine O, Mariette X, Porcher R, Resche-Rigon M, Tharaux P-L, Ravaud P, et al. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: Two randomised controlled trials of the CORIMUNO-19 collaborative group. *Eur Respir J* [Internet]. 2022;2102523. Available from: <http://erj.ersjournals.com/content/early/2022/01/13/13993003.02523-2021.abstract>
 19. Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. *Signal Transduct Target Ther* [Internet]. 2021 [cited 2022 Jul 30];6(1):255. Available from: <https://www.nature.com/articles/s41392-021-00679-0>
 20. Li XY, Du B, Wang YS, Kang HYJ, Wang F, Sun B, et al. The keypoints in treatment of the critical coronavirus disease 2019 patient. *Zhonghua Jie He He Hu Xi Za Zhi* [Internet]. 2020 [cited 2022 Jul 30];43(0):E026. Available from: <https://pubmed.ncbi.nlm.nih.gov/32294811/>
 21. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* [Internet]. 2020 [cited 2022 Jul 30];18(5):1094–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/32220112/>
 22. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *Eur Respir J* [Internet]. 1996 [cited 2022 Jul 30];9(8):1736–42. Available from: <https://pubmed.ncbi.nlm.nih.gov/8866602/>
 23. Huang Y, Guo L, Chen J, Wu M, Zhang C, Liu Z, et al. Serum lactate dehydrogenase level as a prognostic factor for COVID-19: A retrospective study based on a large sample size. *Front Med (Lausanne)* [Internet]. 2021 [cited 2022 Jul 30];8:671667. Available from: <http://dx.doi.org/10.3389/fmed.2021.671667>
 24. Lv X-T, Zhu Y-P, Cheng A-G, Jin Y-X, Ding H-B, Wang C-Y, et al. High serum lactate dehydrogenase and dyspnea: Positive predictors of adverse outcome in critical COVID-19 patients in Yichang. *World J Clin Cases* [Internet]. 2020 [cited 2022 Jul 30];8(22):5535–46. Available from: <https://www.wjgnet.com/2307-8960/full/v8/i22/5535.htm>
 25. Regoli F, Winston GW. Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxy radicals, and hydroxyl radicals. *Toxicol Appl Pharmacol* [Internet]. 1999 [cited 2022 Jul 30];156(2):96–105. Available from: <https://pubmed.ncbi.nlm.nih.gov/10198274/>
 26. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature* [Internet]. 2003 [cited 2022 Jul 30];425(6957):516–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/14520412/>

27. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. *Nucleosides Nucleotides Nucleic Acids* [Internet]. 2008 [cited 2022 Jul 30];27(6):608–19. Available from: <https://pubmed.ncbi.nlm.nih.gov/18600514/>
28. Li G, Wu X, Zhou C-L, Wang Y-M, Song B, Cheng X-B, et al. Uric acid as a prognostic factor and critical marker of COVID-19. *Sci Rep* [Internet]. 2021 [cited 2022 Jul 30];11(1):17791. Available from: <https://www.nature.com/articles/s41598-021-96983-4>
29. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol* [Internet]. 2017 [cited 2022 Jul 30];29(9):401–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/28541437/>
30. Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. *J Crit Care* [Internet]. 2022 [cited 2022 Jul 30];67:172–81. Available from: <http://dx.doi.org/10.1016/j.jcrc.2021.09.023>
31. Guirao JJ, Cabrera CM, Jiménez N, Rincón L, Urra JM. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol* [Internet]. 2020 [cited 2022 Jul 31];128:64–8. Available from: <http://dx.doi.org/10.1016/j.molimm.2020.10.006>
32. Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. *J Transl Med* [Internet]. 2020 [cited 2022 Jul 31];18(1):406. Available from: <http://dx.doi.org/10.1186/s12967-020-02571-x>
33. Researchgate.net. [cited 2022 Jul 31]. Available from: https://www.researchgate.net/publication/341463153_Elevated_levels_of_interleukin-6_and_CRP_predict_the_need_for_mechanical_ventilation_in_COVID-19
34. Bauer A, Korten I, Juchem G, Kiesewetter I, Kilger E, Heyn J. EuroScore and IL-6 predict the course in ICU after cardiac surgery. *Eur J Med Res* [Internet]. 2021;26(1):29. Available from: <http://dx.doi.org/10.1186/s40001-021-00501-1>
35. Matthay MA, Luetkemeyer AF. IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: Who, when, and how?: Who, when, and how? *JAMA* [Internet]. 2021 [cited 2022 Jul 31];326(6):483–5. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2781881>
36. Nih.gov. [cited 2022 Jul 31]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/33631065>
37. Medrxiv.org. [cited 2022 Jul 31]. Available from: <https://www.medrxiv.org/content/10.1101/2021.06.18.21259133v2>